Merck unveils early data on HIV drug it says could be ‘a game changer’
At an all-day meeting for investors last month in a posh Manhattan event space, executives at Merck couldn’t have been more excited about a new HIV drug, MK-8591. They mentioned it 25 times, calling it “a game changer” and talking up its “remarkable properties.”
Why? If effective, it could be used in a new drug combination that might have fewer side effects, the company says. More excitingly, it might be fashioned into an implant that could be given only once a year to prevent patients at high risk from contracting HIV, a boon to public health.
Read Original Article: Merck unveils early data on HIV drug it says could be ‘a game changer’ »
